Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the first FDA awarded under its Material Threat Medical Countermeasure voucher program.
TPOXX, an oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga Gets Priority Review Voucher For First Approved Smallpox Drug").
Priority Review voucher prices have ranged from $67.5 million to $350 million since the first one was issued in 2009. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold one in July for $80.6 million (see "Voucher Equilibrium" and "Kyowa, Ultragenyx Sell Priority Review Voucher For $80.6M").
The medical countermeasure program was created under the 21st Century Cures Act, and awards vouchers for "medical products intended to diagnose, prevent or treat diseases or conditions associated with threats and emerging infectious diseases."
Siga was up $0.27 to $5.10 in early trading Thursday.
(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE